.jpg)
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal
The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.
The British drugmaker is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer as well as autoimmune conditions.
